We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly and Centocor have temporarily suspended enrollment in a late-stage clinical trial of their heart treatment ReoPro after a review of preliminary trial data revealed a potential safety problem with the drug.